Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

STEP 2 Study Group

Research output: Contribution to journalArticlepeer-review

130 Scopus citations

Fingerprint

Dive into the research topics of 'Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences